



IMMUNO

Aktiengesellschaft für chemisch-medizinische Produkte

IMMUNO LTD.
Att. Mr. Nicholson

Arctic House
Rye Lane
Dunton Green
Nr. Sevenoaks
KENT TN14 5HB
G R E A T B R I T A I N

A-1221 Wien, Postfach 20
Industriestraße 67

Telefon: (0222) 2300-0
Telex: 134865/132722/132813 immuno a
Telefax: (0222) 2371 24/230052 bis 58



Vienna, 1990 05 03
4324/Hi

Pack Insert of FEIBA IMMUNO VH

Dear Mr. Nicholson,

As already discussed before we would like to stick to our most recent neutral English pack insert (Code no. 6205820EU06) as largely as possible. From our point of view only two items will have to be modified as follows:

1. The dosage recommendations for prophylactic treatment given in Table 2 should be adapted to Brackmann's latest schedule. A revised version is attached as well as a copy of Brackmann's paper presented in Japan last year on which the revised table is based.
2. Under "Side Effects" the last sentence of the third paragraph ("However, a severe clinical course or fatal outcome after treatment with FEIBA TIM 4 have never been reported.") should be removed.

Awaiting your comments we remain with kind regards

I M M U N O A G

GRO-C

Dipl.Dolm. I. Diernhofer
Head, Licensing Department

Enclosures